Variant report
Variant | nsv9580 |
---|---|
Chromosome Location | chr2:36283694-36285579 |
allele | n/a |
Outlinks | Ensembl   UCSC |
- TF binding region (count:0)
- CpG islands (count:0)
- Chromatin interactive region (count:0)
- LncRNA region (count:0)
- Mature miRNA region (count: 0)
- miRNA target sites (count:0)
No data |
No data |
No data |
No data |
No data |
No data |
No data |

No. | Variant name | Chromosome position | Chromatin state | Related regulatory elements | Target genes | Extended variants | Associated traits |
---|---|---|---|---|---|---|---|
1 | rs147814227 | chr2:36284605-36284606 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
2 | rs536233106 | chr2:36284617-36284618 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
3 | rs370483415 | chr2:36284675-36284676 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
4 | rs567817719 | chr2:36284680-36284681 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
5 | rs186376889 | chr2:36284683-36284684 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
6 | rs576108505 | chr2:36284716-36284717 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
7 | rs190974750 | chr2:36284724-36284725 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
8 | rs10169201 | chr2:36284734-36284735 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
9 | rs112240329 | chr2:36284802-36284803 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
10 | rs538577664 | chr2:36284812-36284813 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
11 | rs113169366 | chr2:36284849-36284850 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
12 | rs113497181 | chr2:36284869-36284870 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
13 | rs114726719 | chr2:36284872-36284873 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
14 | rs560903050 | chr2:36284913-36284914 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
15 | rs572859851 | chr2:36284938-36284939 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
16 | rs931401 | chr2:36284939-36284940 | Enhancers Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | mRNA abundance |
17 | rs78649950 | chr2:36284972-36284973 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
18 | rs6740927 | chr2:36284976-36284977 | Enhancers Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
19 | rs550499537 | chr2:36284984-36284985 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
20 | rs562423364 | chr2:36284991-36284992 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
21 | rs373784426 | chr2:36284999-36285000 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
22 | rs534720220 | chr2:36285030-36285031 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
23 | rs529974257 | chr2:36285049-36285050 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
24 | rs141340080 | chr2:36285053-36285054 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
25 | rs368837548 | chr2:36285064-36285065 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
26 | rs35072547 | chr2:36285128-36285129 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
27 | rs544569301 | chr2:36285129-36285130 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
28 | rs111633935 | chr2:36285130-36285131 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
29 | rs397871811 | chr2:36285138-36285139 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
30 | rs17018101 | chr2:36285217-36285218 | Enhancers Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
31 | rs72865755 | chr2:36285253-36285254 | Enhancers Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
32 | rs534078440 | chr2:36285286-36285287 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
33 | rs182762799 | chr2:36285294-36285295 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
34 | rs550385173 | chr2:36285302-36285303 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
35 | rs571090833 | chr2:36285342-36285343 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
36 | rs113980506 | chr2:36285361-36285362 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
37 | rs191410807 | chr2:36285382-36285383 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
38 | rs149593130 | chr2:36285404-36285405 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
39 | rs183194204 | chr2:36285414-36285415 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
40 | rs187813298 | chr2:36285480-36285481 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
41 | rs192439043 | chr2:36285553-36285554 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
42 | rs305193 | chr2:36285554-36285555 | Enhancers Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
43 | rs10495862 | chr2:36285558-36285559 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
Disease | PMID | Source |
---|---|---|
Breast cancer | 17393978 | CNVD |
Acute lymphoblastic leukemia | 21098271 | CNVD |
Breast cancer | 17603634 | CNVD |
Medulloblastoma | 21979893 | CNVD |
Lynch syndrome | 18415027 | CNVD |
Basal cell lymphoma | 16317097 | CNVD |
Diffuse large b-cell lymphoma | 16317097 | CNVD |
Chronic lymphocytic leukemia | 21546498 | CNVD |
Diffuse large b-cell lymphoma | 18287131 | CNVD |
Ovarian neoplasms | 16753589 | CNVD |
Glioblastoma multiforme | 17387387 | CNVD |
Neuroblastoma | 17533364 | CNVD |
Neuroblastoma | 18923191 | CNVD |
Endometrial cancer | 22040021 | CNVD |
Adrenal tumor | 17535989 | CNVD |
Breast cancer | 21264507 | CNVD |
Basal cell lymphoma | 17053054 | CNVD |
Medulloblastoma | 17522785 | CNVD |
Cancer | 23418310 | CNVD |
Ewing''s sarcoma | 21437220 | CNVD |
Glioblastoma multiforme | 21080181 | CNVD |
Ependymoma | 16718352 | CNVD |
T-cell prolymphocytic leukemia | 19278963 | CNVD |
lymphocytic leukemia | 21291569 | CNVD |
Prostate cancer | 18632612 | CNVD |
Bladder cancer | 21909424 | CNVD |
Thoracic aortic aneurysm | 21092924 | CNVD |
Hodgkin''s lymphoma | 17606441 | CNVD |
Intellectual disability | 22102821 | CNVD |
Cancer | 20164919 | CNVD |
Hodgkin''s lymphoma | 18641027 | CNVD |
Autism | 22495311 | CNVD |
Acute lymphoblastic leukemia | 20435627 | CNVD |
Follicular lymphoma | 20505157 | CNVD |
Autism | 17483303 | CNVD |
Invasive pancreatic ductal carcinoma | 16982739 | CNVD |
Myofibroblastic sarcoma | 19369631 | CNVD |
Esophageal adenocarcinoma | 18519675 | CNVD |
Medulloblastoma | 20607354 | CNVD |
Leukemia | 18628472 | CNVD |
Autism | 19521722 | CNVD |
Autism | 18522746 | CNVD |
Breast cancer | 21364760 | CNVD |
Wilms tumour | 21544195 | CNVD |
Non-small cell lung cancer | 18927303 | CNVD |
Hereditary gingival fibromatosis | 19633868 | CNVD |
Breast cancer | 21785460 | CNVD |
Lung cancer | 18438408 | CNVD |
Myelofibrosis | 22110671 | CNVD |
Breast cancer | 21045282 | CNVD |
Prostate cancer | 21965145 | CNVD |
Breast cancer | 16397240 | CNVD |
Acute lymphoblastic leukemia | 21390130 | CNVD |
Esophageal squamous carcinoma | 21637470 | CNVD |
Neuroblastoma | 21508638 | CNVD |
Neurodevelopmental disorder | 22521361 | CNVD |
Neurocytoma | 17123091 | CNVD |
Autism | 22495309 | CNVD |
small cell lung cancer | 20016488 | CNVD |
Melanoma | 18172304 | CNVD |
Cancer | 16751803 | CNVD |
Non-syndromic sensorineural hearing loss | 17122850 | CNVD |
No. | Chromosome Location | Chromatin state | Cell line | Tissue |
---|---|---|---|---|
1 | chr2:36284600-36284800 | Enhancers | H1 BMP4 Derived Mesendoderm Cultured Cells | ES cell derived |
2 | chr2:36284600-36285800 | Enhancers | Primary T cells from cord blood | blood |
3 | chr2:36284600-36286400 | Enhancers | HUVEC | blood vessel |
4 | chr2:36284800-36286000 | Enhancers | ES-I3 Cell Line | embryonic stem cell |
5 | chr2:36284800-36286200 | Weak transcription | H1 BMP4 Derived Mesendoderm Cultured Cells | ES cell derived |
6 | chr2:36284800-36287600 | Enhancers | Primary hematopoietic stem cells G-CSF-mobilized Male | -- |
7 | chr2:36284800-36287800 | Enhancers | hESC Derived CD184+ Endoderm Cultured Cells | ES cell derived |
8 | chr2:36284800-36287800 | Enhancers | Primary hematopoietic stem cells G-CSF-mobilized Female | -- |
9 | chr2:36285000-36285400 | Enhancers | Primary T helper cells PMA-I stimulated | -- |
10 | chr2:36285200-36285400 | Enhancers | Primary hematopoietic stem cells | blood |
11 | chr2:36285200-36285400 | Enhancers | Fetal Intestine Small | intestine |
12 | chr2:36285200-36285600 | Enhancers | HUES6 Cell Line | embryonic stem cell |
13 | chr2:36285200-36286200 | Enhancers | iPS-18 Cell Line | embryonic stem cell |
14 | chr2:36285200-36287800 | Enhancers | Primary hematopoietic stem cells short term culture | blood |
15 | chr2:36285200-36288000 | Enhancers | Fetal Intestine Large | intestine |
16 | chr2:36285400-36286200 | Weak transcription | Primary hematopoietic stem cells | blood |
17 | chr2:36285400-36286200 | Weak transcription | Fetal Intestine Small | intestine |